Business
Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
(TheNewswire) LONDON, ONTARIO – TheNewswire - January 5, 2022 ...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n LONDON, ONTARIO –\n \n \n TheNewswire -\n \n \n January 5, 2022 – Sernova Corp. (TSXV:SVA)\n(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine\nand cell therapy therapeutics company focused on developing a\npotential ‘functional cure’ for type 1 diabetes (T1D) and other\nchronic diseases, is pleased to announce that\n \n \n \n \n new interim results from the\nongoing safety, tolerability and efficacy Phase I/II clinical trial of\nSernova’s Cell Pouch™ will be released on January 10, 2022.\n \n \n \n \n Originally, it was planned that Dr. Piotr Witkowski,\nprincipal investigator of Sernova’s Phase I/II clinical trial would\npresent an update in a poster session at the American Society of\nTransplant Surgeons (ASTS) 22nd Annual “State of the Art” Winter\nSymposium on January 13, 2022, but the conference was postponed\nyesterday until the end of July 2022 because of the ongoing COVID-19\npandemic.\n \n \n \n \n “We are pleased to be announcing these new interim\ndata earlier than anticipated in conjunction with the J.P. Morgan\nconference which is one of the premier international healthcare\nconferences,”\n \n \n \n said\n \n \n \n Dr.\n \n \n \n Philip\n \n \n \n Toleikis, President & CEO of Sernova.\n \n \n \n \n ABOUT THE J.P. MORGAN HEALTHCARE\nCONFERENCE\n \n \n \n \n The annual J.P. Morgan Healthcare Conference is the\nlargest and most informative healthcare investment symposium in the\nindustry which connects global industry leaders, emerging fast growth\ncompanies, innovative technology creators and members of the\ninvestment community. The J.P. Morgan 40th Annual Healthcare\nConference (JPM 2022) will take place virtually, January 10-13, 2022.\n \n \n \n \n ABOUT SERNOVA\n \n \n \n \n Sernova is developing regenerative medicine therapeutic\nsolutions using a medical  device (Cell Pouch) and immune protected\ntherapeutic cells / tissues (i.e. human donor cells, corrected human\ncells and stem cell-derived cells) to improve the treatment and\nquality of life of people with chronic metabolic diseases such as\ninsulin-dependent diabetes, blood di...